04:43 , Dec 15, 2018 |  BioCentury  |  Product Development

O’Day’s expansive task at Gilead

A fresh executive team and a track record of building deep portfolios could allow incoming Gilead Sciences Inc. chairman and CEO Daniel O’Day to do what his predecessors couldn’t: make Gilead a leader outside of...
18:29 , Aug 31, 2018 |  BC Week In Review  |  Company News

Sierra Oncology acquires momelotinib from Gilead

Sierra Oncology Inc. (NASDAQ:SRRA) acquired momelotinib (formerly CYT387) from Gilead Sciences Inc. (NASDAQ:GILD) for $3 million up front and up to $195 million in milestones. Gilead is also eligible for tiered royalties ranging from mid-teens...
19:09 , Nov 16, 2016 |  BC Extra  |  Clinical News

Mixed Phase III results for Gilead's momelotinib in myelofibrosis

Gilead Sciences Inc. (NASDAQ:GILD) announced mixed results from two Phase III studies of momelotinib (formerly CYT387) to treat myelofibrosis. The candidate showed non-inferiority to Jakafi ruxolitinib on the SIMPLIFY-1 trial's primary endpoint, but failed to...
02:27 , Feb 12, 2016 |  BC Extra  |  Clinical News

Incyte discontinues Jakafi trials in solid tumors

Incyte Corp. (NASDAQ:INCY) reported 4Q15 and 2015 revenues that beat expectations but fell $6.80 to $65.51 on Thursday after it said it would discontinue all ongoing trials of myelofibrosis drug Jakafi ruxolitinib in solid tumors,...
08:00 , Jan 5, 2015 |  BioCentury  |  Finance

Back for more

About three years after closing its last fund, Vivo Capital (formerly Vivo Ventures) has come back for more. The firm raised $428 million for an eighth fund, according to a December SEC filing. Vivo invests...
07:00 , Sep 8, 2014 |  BC Week In Review  |  Company News

ProNAi management update

ProNAi Therapeutics Inc. , Kalamazoo, Mich.   Business: Cancer   Hired: Nick Glover as president and CEO, formerly president and CEO of YM BioSciences Inc. , which Gilead Sciences Inc. acquired; he succeeds Mina Sooch...
07:00 , May 12, 2014 |  BC Week In Review  |  Clinical News

Nimotuzumab: Phase III discontinued

In April, Daiichi Sankyo discontinued a double-blind, placebo-controlled, Japanese Phase III trial evaluating IV nimotuzumab with concurrent chemoradiotherapy as first-line treatment of unresectable and locally advanced squamous cell lung cancer. The company said the decision...
07:00 , Apr 7, 2014 |  BC Week In Review  |  Company News

Pulmokine, NIH cardiovascular news

Pulmokine received a contract worth up to $1.5 million from NIH's National Heart, Lung, and Blood Institute (NHLBI) to develop an inhaled platelet derived growth factor receptor (PDGFR) kinase inhibitor to treat pulmonary arterial hypertension...
07:00 , Aug 19, 2013 |  BC Week In Review  |  Company News

Tekmira management update

Tekmira Pharmaceuticals Corp. (TSX:TKM; NASDAQ:TKMR), Burnaby, B.C.   Business: Cancer, Drug delivery   Hired: Mark Kowalski as SVP and CMO, a newly created position, formerly VP of regulatory affairs and CMO of YM BioSciences Inc....
08:00 , Feb 18, 2013 |  BC Week In Review  |  Company News

Gilead, YM BioSciences deal

Gilead completed its acquisition of YM BioSciences for $2.95 per share, or about $510.3 million based on 173 million fully diluted YM shares at Sept. 30, 2012. YM will become a Gilead subsidiary (see BioCentury,...